GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 06:37:26 03/06/2024 pm IST 5-day change 1st Jan Change
1,611 GBX -8.80% Intraday chart for GSK plc -7.00% +11.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK Says Cancer Drug Jemperli Shows 100% Clinical Response Rate in Long-Term Data From Mid-Stage Trial MT
GSK immunotherapy bowel cancer drug works for 100% of patients AN
Sector Update: Health Care MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Economic Data MT
GSK to Face Trials Over Zantac Cancer Allegations; Shares Tumble Pre-Bell MT
GSK : Sell rating from JP Morgan ZD
GSK : Deutsche Bank reiterates its Buy rating ZD
FTSE 100 up, while Labour commits to defence AN
GSK : Goldman Sachs remains Neutral ZD
GSK Shares Plunge After Delaware Ruling Allowing Jury Trials for Zantac Case -- Update DJ
GSK Interim Analysis of Phase III Trial for Blood Cancer Therapy Shows Promise MT
European Midday Briefing : Mood Improves on Fed Rate Cut Hopes DJ
News Highlights : Top Company News of the Day - Monday at 5 AM ET DJ
GSK Shares Plunge After Delaware Ruling on Zantac DJ
GSK vows to appeal adverse Delaware court ruling on Zantac AN
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed RE
Stocks up amid slew of manufacturing PMIs AN
London stocks open nearly 1% higher, eye European rate cut; GSK slumps RE
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to move forward RE
FTSE 100 seen up; GSK defends ranitidine cancer claim AN
European shares kick-start week higher, focus on ECB rate verdict RE
GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases MT
GSK's Blenrep Combination Reduce Risk Of Disease Progression, Death By Nearly 50% RE
Gsk PLC - Statement Zantac (Ranitidine) Litigation RE
GSK Says Belantamab Mafodotin Combination Reduced Risk Of Disease Progression Or Death By Nearly 50% In Relapsed/Refractory Multiple Myeloma RE
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
17.66 GBP
Average target price
20.26 GBP
Spread / Average Target
+14.69%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GlaxoSmithKline to Acquire Sierra Oncology for $1.9 Billion